Geode Capital Management LLC Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Geode Capital Management LLC boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,381,985 shares of the biotechnology company's stock after acquiring an additional 137,989 shares during the period. Geode Capital Management LLC owned 2.31% of ADMA Biologics worth $107,606,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ADMA. Calamos Advisors LLC raised its stake in shares of ADMA Biologics by 8.3% in the second quarter. Calamos Advisors LLC now owns 603,003 shares of the biotechnology company's stock valued at $6,742,000 after buying an additional 46,405 shares during the period. Bank of New York Mellon Corp raised its stake in ADMA Biologics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 766,544 shares of the biotechnology company's stock valued at $8,570,000 after acquiring an additional 49,631 shares during the period. Viewpoint Capital Management LLC lifted its holdings in ADMA Biologics by 32.4% during the second quarter. Viewpoint Capital Management LLC now owns 20,416 shares of the biotechnology company's stock valued at $228,000 after purchasing an additional 5,000 shares during the last quarter. Rhumbline Advisers boosted its position in ADMA Biologics by 5.4% during the second quarter. Rhumbline Advisers now owns 310,539 shares of the biotechnology company's stock worth $3,472,000 after purchasing an additional 15,844 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of ADMA Biologics by 192.6% in the second quarter. Victory Capital Management Inc. now owns 84,046 shares of the biotechnology company's stock worth $940,000 after purchasing an additional 55,322 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company's stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Price Performance

NASDAQ:ADMA traded up $0.20 during mid-day trading on Thursday, hitting $17.90. 2,074,536 shares of the stock traded hands, compared to its average volume of 3,559,266. The business's 50-day moving average price is $18.90 and its 200 day moving average price is $16.24. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market cap of $4.23 billion, a PE ratio of 63.93 and a beta of 0.70. ADMA Biologics, Inc. has a 12-month low of $4.06 and a 12-month high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. During the same period in the previous year, the business earned $0.01 EPS. On average, analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on ADMA. HC Wainwright upped their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.